Risperidone

Risperidonum

For medical students2 min readUpdated 2026-10-10

Risperidone is a potent atypical antipsychotic drug belonging chemically to the benzisoxazole derivatives. In modern psychopharmacology, this drug holds a unique position due to its dose-dependent profile and efficacy in treating severe forms of schizophrenia refractory to conventional therapy.

ClassBenzisoxazole derivative

Targets5-HT2A receptors, D2 receptors, α-adrenergic receptors, H1 receptors

Dosing scheduleOnce daily (due to a long-acting active metabolite)

Adverse effectHigh risk of extrapyramidal symptoms (EPS) due to lack of muscarinic blockade

Mechanism of Action and Receptor Targets

The mechanism of action is based on the selective blockade of specific central nervous system receptors. Primarily, the molecule binds to central serotonin $5-HT_{2A}$ receptors and dopamine $D_2$ receptors. Additionally, the drug blocks $\alpha$-adrenergic and histamine $H_1$ receptors.

However, the most clinically significant feature of its receptor profile is what the drug does not bind to. It exhibits virtually no affinity for muscarinic acetylcholine receptors. In clinical practice, this is critical. Many other antipsychotics possess concomitant anticholinergic activity that helps mitigate or prevent extrapyramidal symptoms (movement disorders). Due to the complete absence of this protective anticholinergic effect, risperidone induces extrapyramidal symptoms significantly more often than other atypical antipsychotics.

Dose-Dependent Pharmacodynamics

An interesting property of the molecule is the dose-dependence of its pharmacological profile. Experimental data show that the classification of the drug can literally shift depending on the administered dose. This phenomenon is driven by changes in the receptor occupancy ratio (the balance between serotonin and dopamine blockade).

Low-dose administration: At low doses, the agent exhibits classical atypical antipsychotic properties, providing antipsychotic efficacy with a minimal risk of severe neurological side effects.
High-dose administration: As the concentration increases, the action profile shifts sharply. The drug begins to behave like a typical antipsychotic. Clinically, this is manifested by a high propensity for severe extrapyramidal symptoms.

Pharmacokinetics and Active Metabolite

Pharmacokinetic parameters determine the convenience of the drug in routine clinical practice. After entering the systemic circulation, the parent compound undergoes active metabolism, primarily yielding the active metabolite known as 9-hydroxyrisperidone (paliperidone).

A key characteristic of this metabolite is its half-life ($t_{1/2}$). For 9-hydroxyrisperidone, this parameter is significantly longer than that of the parent drug, reaching approximately 24 hours.

The practical significance of this pharmacokinetic property is profound. Thanks to the prolonged circulation of the active metabolite in the blood, frequent tablet administration is unnecessary. Clinicians can prescribe the drug once daily, maintaining stable therapeutic concentrations and antipsychotic efficacy throughout the day.

Clinical Indications

In clinical practice, the drug has a well-defined niche. The primary indication is the comprehensive management of schizophrenia.

It is especially valuable in managing complex psychiatric cases, demonstrating high clinical efficacy in treatment-resistant forms of the disease. Specifically, it is successfully used when the pathology is completely refractory to conventional high-potency antipsychotics such as haloperidol.

Mnemonic

To easily remember the receptor profile for your exam, use this mnemonic: "Serotonin and Dopamine Attack Histamine, but bypass Muscarinic Cholinergic receptors." This breaks down as follows: the drug blocks Serotonin, Dopamine, Alpha-adrenergic, and Histamine receptors, but has a complete lack of effect on Muscarinic receptors (which accounts for its frequent extrapyramidal side effects).

Frequently asked questions

What are the indications for risperidone?

Risperidone is used to treat a wide range of psychiatric disorders. The primary indication is schizophrenia, including treatment-resistant cases refractory to haloperidol.

Indications include:

Control of positive symptoms — reduction of delusions, hallucinations, and catatonic disturbances.
Management of negative symptoms — mitigation of social withdrawal, apathy, and blunted affect.
Behavioral control — in personality disorders, neuroses, organic brain syndromes, and autism spectrum disorders.
Adjunctive uses — management of behavioral disturbances in dementia.
Acute exacerbations — suppressing the progression of acute psychotic episodes.

What side effects does risperidone cause?

Risperidone can cause neurological side effects and significant sedative actions.

Main adverse reactions include:

Extrapyramidal symptoms (EPS) — occurring more frequently than with other atypical antipsychotics due to the lack of intrinsic anticholinergic activity. These symptoms manifest primarily at higher doses when the drug behaves like a typical antipsychotic.
Sedation and weight gain — common metabolic and autonomic side effects associated with $\alpha_1$ and $H_1$ antagonism.

Notably, the overall probability of neuroleptic malignant syndrome with risperidone is substantially lower than with typical high-potency antipsychotics.

Why does risperidone provoke extrapyramidal symptoms more frequently than other atypical agents?

The primary reason lies in its receptor profile. The drug has virtually no affinity for muscarinic receptors. In psychopharmacology, concomitant anticholinergic activity helps mitigate extrapyramidal symptoms. Because this protective effect is absent here, the risk of movement disorders increases.

How does dosage affect the pharmacological class of the drug?

Changing the dose alters the serotonin-to-dopamine receptor occupancy ratio. While low doses act as a mild atypical antipsychotic, high doses confer properties typical of first-generation antipsychotics, leading to extrapyramidal side effects.

What enables once-daily dosing of the medication?

The parent drug is metabolized in the body into an active metabolite, 9-hydroxyrisperidone. The half-life of this metabolite is 24 hours, significantly exceeding the half-life of the parent compound and ensuring sustained therapeutic efficacy.

Go deeper

Detailed analysis of the selective blockade mechanism at serotonin ($5-HT_{2A}$) and dopamine ($D_2$) receptors.
Pathogenesis of extrapyramidal symptoms in the absence of muscarinic receptor blockade.
Significance of the serotonin/dopamine receptor occupancy ratio in classifying antipsychotics.
Pharmacokinetics of 9-hydroxyrisperidone: formation pathways and elimination characteristics.
Criteria for treatment-resistant schizophrenia and strategies for transitioning patients from haloperidol.